In addition, new research in metabolic diseases contributed to higher research and development costs in the second half of 2000 compared to the second half of 1999. Such fees had previously been recognized when received, but now are being recognized over the term of the contract. Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs which act through the regulation of gene expression. Tularik programs address cancer, viral diseases, diabetes, obesity, inflammation, immune disorders, lipid disorders and bacterial diseases, and a class of targets known as orphan nuclear receptors. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
Press releases are only accurate as of their respective dates.
Tularik does not undertake to update this information included in any press release.